Loading
Loading
Research Overview
Dual glucagon and GLP-1 receptor agonist; the glucagon component drives increased hepatic fatty acid oxidation and thermogenesis while GLP-1 activity contributes to appetite suppression and insulin sensitisation.
Overview
Survodutide is a synthetic dual agonist peptide that engages both GLP-1 and glucagon receptors. Preclinical studies have investigated its metabolic effects in animal models, with particular attention to liver biology, where the glucagon receptor component may contribute to hepatic fat mobilisation while GLP-1 receptor engagement modulates inflammatory pathways.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, survodutide (bi 456906) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Dual glucagon and GLP-1 receptor agonist; the glucagon component drives increased hepatic fatty acid oxidation and thermogenesis while GLP-1 activity contributes to appetite suppression and insulin sensitisation.
Support
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.